Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.
Last trade$13.90
Day change-$0.005 (-0.04%)
Day range$13.88 – $13.91
Volume1,527,411
Market cap$3.65B
OpenXNYS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$3.65B
Price / earnings
17.14×
Price / book
3.06×
Price / sales
0.6×
EV / sales
1.76×
EV / EBITDA
7.1×
Profitability
Earnings per share
$0.81
Return on assets
1.59%
Return on equity
17.85%
Dividend yield
0.55%
Liquidity and leverage
Debt / equity
7.17×
Current ratio
2.02×
Quick ratio
1.51×
Cash ratio
0.55×
Cash flow
Price / cash flow
4.33×
Price / free cash flow
5.41×
Free cash flow
$675M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for OGN, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$1.57B
$1.56B
$1.46B
$1.51B
$1.6B
$1.59B
$1.51B
$1.59B
Cost of revenue
$705M
$711M
$677M
$766M
$745M
$720M
$672M
$696M
Gross profit
$869M
$847M
$783M
$741M
$857M
$874M
$841M
$896M
Selling, general and administrative
$421M
$434M
$424M
$433M
$415M
$453M
$420M
$470M
Research and development
$83M
$91M
$93M
$91M
$84M
$95M
$102M
$130M
Total operating expenses
$504M
$525M
$548M
$832M
$499M
$550M
$608M
$608M
Operating income
$365M
$322M
$235M
-$91M
$358M
$324M
$233M
$288M
Interest expense
-$106M
-$108M
-$111M
-$121M
-$128M
-$131M
-$124M
-$132M
Income before taxes
$255M
$183M
$213M
-$148M
$243M
$229M
$101M
$129M
Income taxes
$91M
$75M
$67M
$57M
$83M
$84M
$14M
$20M
Net income
$164M
$108M
$146M
-$205M
$160M
$145M
$87M
$109M
Net income attributable to common shareholders
$164M
$108M
$146M
-$205M
$160M
$145M
$87M
$109M
EBITDA
$447M
$402M
$352M
$313M
$450M
$415M
$403M
$373M
Basic earnings per share
$0.62
$0.41
$0.56
-$0.79
$0.61
$0.56
$0.34
$0.42
Diluted earnings per share
$0.60
$0.40
$0.55
-$0.78
$0.61
$0.56
$0.33
$0.42
Recent news
Company coverage with links to the original publishers.
Organon (OGN), a pharmaceutical company, is attracting investor attention with stock returns of +0.6% over the past month. The company has a Zacks Rank #3 (Hold) rating, with current quarter earnings expected at $0.83 per share (+31.8% YoY), though full-year earnings are projected to decline 7.4%. Revenue growth remains modest at -2.1% for the current fiscal year. The stock is trading at a discount to peers with an A valuation grade, suggesting it may perform in line with the broader market in the near term.
Organon (OGN), a pharmaceutical company, has been trending on Zacks.com. The stock returned +0.2% over the past month, outperforming the S&P 500's -1.2% decline. However, earnings estimates show a -9.9% decline for the current quarter and -7.9% for the current fiscal year, though next year is expected to grow +7%. The company holds a Zacks Rank #3 (Hold) rating and trades at a valuation discount to peers with an A grade on the Value Style Score.
Organon (OGN) is receiving significant investor attention. The pharmaceutical company shows declining earnings estimates for the current fiscal year (-7.9%) but modest growth expected for next year (+7%). Revenue growth remains flat to slightly negative. With a Zacks Rank #3 (Hold) rating and a Grade A valuation score indicating the stock trades at a discount to peers, the company is expected to perform in line with the broader market in the near term.
Organon (OGN), a pharmaceutical company, is being closely watched by investors. The stock has underperformed the S&P 500 over the past month (-0.4% vs +0.6%). Earnings estimates remain unchanged with expected EPS of $0.91 for the current quarter (down 9.9% YoY) and $3.37 for the fiscal year (down 7.9% YoY). Revenue is expected to decline slightly. The company received a Zacks Rank #3 (Hold) rating, suggesting it may perform in line with the broader market. However, it is trading at a discount to peers based on valuation metrics.
Brodsky & Smith law firm has announced investigations into multiple merger transactions, including Apogee Therapeutics (acquired by AbbVie for $135.11/share), Roku (acquired by Fox for $160/share), TruBridge (acquired by Inventurus for $26.25/share), and Organon (acquired by Sun Pharmaceutical for $14/share). The investigations focus on whether the respective boards breached fiduciary duties by failing to conduct fair processes and whether deal consideration provides fair value to shareholders.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
Ex-dividend
Amount / share
Pay date
Type
Nov 9, 2026
$0.02
Dec 10, 2026
recurring
Aug 14, 2026
$0.02
Sep 10, 2026
recurring
May 11, 2026
$0.02
Jun 11, 2026
recurring
Feb 23, 2026
$0.02
Mar 12, 2026
recurring
Nov 20, 2025
$0.02
Dec 11, 2025
recurring
Stock splits
Historical share-structure events and their execution dates.